Cancer drug margins are being capped. Hospitals should show prices first
Published · By Gaurav Phogat
Business Standard reported on 8 October 2026 that the Centre will cap trade margins on 110 non-scheduled cancer drugs at 30% of MRP, with MRPs expected to fall by up to 70%. On 12 October the Supreme Court asked why the cap stops at cancer. For hospitals, this is no longer a pharmacy margin issue. It is an oncology trust issue.
What happened
Business Standard reported on 8 October 2026 that trade margins on 110 non-scheduled anti-cancer drugs, 35 of them patented, will be capped at 30% of MRP. Officials expect MRPs to fall by up to 70%, saving an estimated Rs 2,500 crore a year. A DGHS committee found trade margins of 170% to 700% on cancer drugs at various outlets. Non-scheduled formulations are about 82% of the domestic market.
This article is part of the Industry Watch series, best read in order from the pillar.
At a hearing on 12 October, Bar and Bench reported, the Supreme Court asked why the cap applies only to cancer drugs, citing a stent with a Rs 5,000 retailer price and a Rs 25,000 MRP and a saline drip line with an Rs 11 MRP sold for Rs 270. Officials have said caps could later extend to consumables such as IV kits and catheters. The next hearing is on 27 October.
My take
Every oncology marketer I know has fought the same objection: “the same drug is cheaper outside.” Families of cancer patients compare prices more than any other patient group, because the treatment runs for months and the bills repeat. This cap gives them a public number to compare against.
So the hospital that waits for the notification and quietly reprices will look like it was caught. The one that publishes its oncology drug pricing, explains the cap and shows the new bill will look like it was on the patient’s side. Same economics, very different brand outcome.
What most coverage missed
Most coverage is about pharma margins and hospital earnings. The bigger shift is in search and word of mouth. Once MRPs drop, cancer patients and their families will search drug names with “price”, share screenshots in WhatsApp groups and ask every hospital the same question. Oncology content that ignores cost will lose that conversation to pharmacy apps and patient forums.
The Court’s examples were consumables, not cancer drugs. That tells me the next round of scrutiny will land on line items most hospitals have never had to explain.
What I would do
- Publish a plain language page on the cap: which drugs, what changes for the patient, and when.
- Give oncology coordinators a scripted, honest answer on price, logged in the CRM so you can see which questions repeat.
- Show itemised estimates for chemotherapy cycles before admission, not after discharge.
- Audit consumable pricing now, before the next hearing does it for you.
What to watch
- The final list of covered drugs and the notification date.
- The Supreme Court hearing on 27 October and any move to extend caps to consumables and devices.
Source: Business Standard. Figures as reported at the time of writing.
Sources and further reading
- Bar and Bench reported (barandbench.com)
- Business Standard (business-standard.com)
Questions people ask
As reported by Business Standard on 8 October 2026, the Centre will cap trade margins on 110 non-scheduled anti-cancer drugs at 30% of MRP. Trade margin is the gap between the price the manufacturer charges the trade and the price the patient pays.
Officials expect MRPs on covered drugs to fall by up to 70%, with estimated savings of Rs 2,500 crore a year. The exact list of covered brands is still being finalised.
Officials have said margin caps could later cover other non-scheduled formulations and consumables such as IV kits and catheters. The Supreme Court has questioned why the cap is limited to cancer drugs and will hear the matter again on 27 October.
Explain clearly which drugs are covered, when prices change and what it means for their bill, and share itemised estimates for treatment cycles before admission.
Read my takes first in Google Search
